Pharmacodynamic Study of Cilostazol in Healthy Volunteers

Inclusion Criteria: * Healthy Caucasian male subjects * Able to read, to write and to fully understand German language * Provision of written informed consent before screening and baseline * BMI between 19.0 and 30.0 kg/m2, inclusive and body weight between 50.0 and 100.0 kg, inclusive * Good general health as determined by the investigator by medical history, physical examination, vital signs, electrocardiogram, baseline and safety lab Exclusion Criteria: * Personal or family history of bleeding disorders, or reasonable suspicion of vascular malformations, including aneurysms * Known predisposition to bleeding (e.g. active peptic ulceration, recent (within 6 month) haemorrhagic stroke, proliferative diabetic retinopathy, poorly controlled hypertension) * Use of antibiotics within thirty (30) days prior to screening and until baseline visit * Clinically significant abnormalities in medical history, physical examination, vital signs, electrocardiogram, baseline and safety lab * Supine pulse rate \> 100 beats/min or \<50 beats/min * Systolic blood pressure \<100 or \>140 mmHg * Diastolic blood pressure \<50 or \>90 mmHg * Concomitant use of any other medication including over-the-counter preparations